Salute e Benessere

Tecan appoints Mukta Acharya Head of the Life Sciences Business division

Tecan appoints Mukta Acharya Head of the Life Sciences Business divisionMännedorf, Switzerland, June 24, 2024 –The Tecan Group (SIX Swiss Exchange: TECN) announced today that Mukta Acharya, currently serving as President, Tecan Americas, has been appointed the new Head of the Life Sciences Business division and a member of the Management Board of the Tecan Group. She is expected to assume her new position on August 1, 2024.Dr. Klaus Lun, Head of the Life Sciences Business since 2017...

EMA Approves Biocon Biologics' New mAbs Facility in India and Renews GMP…

"These GMP certifications across our manufacturing sites in India and Malaysia reflect Biocon Biologics' continued compliance with the highest standards of quality and our unwavering commitment to addressing patient needs globally." - Company Spokesperson "These GMP certifications across our manufacturing sites inIndiaandMalaysiareflect Biocon Biologics' continued compliance with the highest standards of quality and our unwavering commitment to addressing patient needs globally...

Navamedic and Orion Corporation sign License & Supply Agreement for Flexilev® in…

"The agreement with Orion to market and sell Flexilev in Europe represents a major milestone as part of the commercialization strategy for Flexilev. Since acquiring the product last year, we have identified several significant growth opportunities for Flexilev, with focus on signing an agreement for Europe where we already have sales in our home turf Scandinavia and marketing authorizations in several other countries. Orion has long-standing experience in the field of neurological diseases…

Artificial Intelligence (AI) in Healthcare Market to Grow at 38.2% CAGR by 2031…

Download a detailed overview: Download a detailed overview: https://www.skyquestt.com/sample-request/artificial-intelligence-in-healthcare-market Artificial Intelligence (AI) in Healthcare Market Overview: Segments covered in Artificial intelligence (AI) in healthcare Market are as follows: Request Free Customization of this report: https://www.skyquestt.com/speak-with-analyst/artificial-intelligence-in-healthcare-market Software to Remain Quintessential in...

Venous Thromboembolism Treatment Market to be Worth $4.40 Billion by 2030 -…

Venous thromboembolism occurs when a blood clot is formed in the veins of the arms or legs and moves through the bloodstream. It obstructs blood and oxygen flow, causing tissue and organ damage. Deep vein thrombosis and pulmonary embolism are both signs and symptoms of venous thromboembolism. These symptoms and the condition itself can be treated using certain devices such as thrombectomy devices, inferior vena cava filters, compression pumps, stockings, and other devices. Venous...

Thermal Cyclers Market Worth 1.86 Billion 2031- Exclusive Report by InsightAce…

Thermal Cyclers Market Report Scope: Thermal Cyclers Market Report Scope: Download Free Sample and ToC of the Report: https://www.insightaceanalytic.com/request-sample/2535 Thermal cyclers are essential tools in molecular biology research and diagnostics. They work by repeatedly heating and cooling a reaction mixture containing DNA, primers, DNA polymerase, and nucleotides. This cycling process allows the DNA to be replicated millions of times, creating copies of the target...

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; June 24, 2024 – Genmab A/S (Nasdaq: GMAB).On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16, 2024.The following transactions were executed under the program from June 17, 2024, to June 21, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)...

StickIt Technologies Inc Announces Reorganization in StickIt Thailand Ltd and…

"The world's cannabis industry is facing many challenges - which affects most companies in the industry and probably affects the share value. It is necessary to reduce costs and try to increase our technology sales worldwide. These actions will save the company about $120,000 CAD a year," concluded Eli Ben Haroosh, CEO of StickIt Technologies Inc. "The world's cannabis industry is facing many challenges - which affects most companies in the industry and probably affects the share…

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 24 June 2024– On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the…

Buyback of Class B shares in Essity during week 25, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...

Sun Pharma Completes Taro Merger

Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, said, "We are pleased with the successful completion of Taro merger process. This milestone marks a significant step forward for both organizations, allowing us to effectively leverage each other's strengths and capabilities. Together, we are excited about starting this new chapter and creating a more robust, successful future for the combined entity." Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, said…

TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the…

TOFIDENCE™ complements existing portfolio of immunology biosimilars commercialized by BiogenCambridge, Mass., June24, 2024(GLOBE NEWSWIRE) -- BiogenInc. (Nasdaq: BIIB) announced that the European Commission (EC) has granted approval for TOFIDENCE TM, a biosimilar monoclonal antibody referencing ROACTEMRA ®1. The intravenous formulation of TOFIDENCE has been granted marketing authorization by the EC for the treatment of moderate to severe active rheumatoid arthritis,...

Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt…

Pelareorep combination therapy advancing towards registration-enabling study in pancreatic cancer Pelareorep combination therapy advancing towards registration-enabling study in pancreatic cancer SAN DIEGOandCALGARY, AB,June 24, 2024/PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced thatMatt Coffey, PhD, President and Chief Executive Officer of Oncolytics will...

BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug…

Designation is based onpre-clinical data and data from an ongoing Phase 1/2 trial for BNT324/DB-1311, with antitumor activity and a manageable safety profile demonstrated by preliminary Phase 1/2 clinical datafrom patients with advanced or metastatic solid tumors1, 2With the Fast Track designation,the development of BNT324/DB-1311 can benefit from more frequent engagement with the U.S. Food and Drug Administration (“FDA”) to support development and expedite regulatory review...

Vitamin K2 Market worth $265 million by 2029 - Exclusive Report by…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=80962397 Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=80962397 Browse in-depth TOC on "Vitamin K2 Market" 80 – Tables 40 – Figures200 – Pages Market growth for Vitamin K2 has been further facilitated by increasing consumer awareness and preference for health and wellness products. As populations age, there is a growing awareness and concern about maintaining...

Wingderm® Shines at IMCAS Asia 2024 with the Innovative Aesthetic Solutions

Throughout the exhibition, Derma Innovation, Wingderm®'s distributor in Thailand, has provided substantial support and assistance. With the local advantages of Derma Innovation, Wingderm® can communicate with visitors more effectively, enhancing their trust and recognition of Wingderm®'s products and services. Throughout the exhibition, Derma Innovation, Wingderm®'s distributor inThailand, has provided substantial support and assistance. With the local advantages of Derma Innovation,...

First gene therapy for prevalent pathologies in neurology receives FDA IND…

EG110A to start Phase 1b/2a clinical study in Neurogenic Detrusor Overactivity (NDO) patients NDO is a severe bladder condition affecting millions of patients living with Spinal Cord Injury, Multiple Sclerosis, Parkinson's disease and other neurological disordersOther severe pathologies of the bladder to be investigated following this studyPreclinical data show EG110A's potential for long-lasting efficacy on urinary continence and to address shortcomings of existing therapiesOpens...

COSRX Hero Products Awarded "Amazon Choice" Badges As UK Shoppers Demand for…

Amazon's Choice is a coveted accolade awarded to products that have received high ratings, are well-priced, and are available to ship immediately. This endorsement not only signifies superior quality and customer satisfaction but also highlights the product's reliability and the positive experiences of numerous users. Amazon's Choice is a coveted accolade awarded to products that have received high ratings, are well-priced, and are available to ship immediately. This endorsement not only...

PolTREG's type-1 diabetes Treg cell therapy PTG-007 demonstrates long-term…

PTG-007 administration resulted in improved remission and insulin secretion Patients monitored for up to 12 yearsPlanned pivotal Phase 2/3 study is final step for PolTREG to bring PTG-007 to market Gdańsk, Poland – 24 June 2024– PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces that its polyclonal Treg cell therapy PTG-007 demonstrated...

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the…

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies NANTES, France, June 24, 2024 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced that the Company has entered into a commercial and revenue sharing agreement with leading global cancer center.This exclusive and worldwide agreement with Memorial Sloan Kettering Cancer Center (MSK) covers OSE Immunotherapeutics' patent rights and jointly...

Roche launches new analytical units for cobas® pro integrated solutions…

The cobas® c 703 and cobas® ISE neo analytical units, deliver higher testing capacity and increased automation helping to improve laboratory workflows and advance patient care.The new cobas c 703 analytical unit offers industry-leading high throughput clinical chemistry testing 1with up to 2,000 tests per hour and 70 reagent positions, doubling the existing clinical chemistry throughput on cobas pro integrated solutions.The new cobas ISE neo analytical unit delivers more...

Valneva Announces Health Canada Approval of the World's First Chikungunya…

Saint-Herblain (France), June 24, 2024–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has approved IXCHIQ ®, Valneva's single-dose vaccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. This decision marks the second approval the Company has received for IXCHIQ ®following approval from the U.S. Food and Drug Administration (FDA) in November 2023. The European...

AstriVax enters clinical phase with its novel vaccine platform technology

The first participants have been dosed in SAFYR, a Phase I clinical trial to test the safety and efficacy of two prophylactic vaccines developed with AstriVax technology. The study will also provide clinical proof of concept for the company's platform technology. Following these first-in-human data, AstriVax plans to advance its immunotherapies for chronic Hepatitis B to clinical development. Leuven - June 24, 2024- The first participants have been dosed in a Phase I clinical...

Juniper Biologics Expands Distribution Rights for Caris Life Sciences' Molecular…

Juniper Biologics is committed to driving positive change in the pharmaceutical industry on a global scale. Aligned with its mission to deliver transformative therapies through bold scientific innovation, Juniper's collaboration with Caris will enhance access to quality treatments for patient communities in the Middle East and Africa. Juniper continues to pursue impactful partnerships aimed at uplifting communities and individuals, especially in underserved regions where access to advanced…

Altri Comunicati